Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators

[thumbnail of Open Access]
Preview
Text (Open Access)
· Available under License Creative Commons Attribution Non-commercial Share Alike.
· Please see our End User Agreement before downloading.
| Preview

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y. orcid id iconORCID: https://orcid.org/0000-0001-8706-5154, Zaldivia, M. T. K., Jandrot-Perrus, M., Schäfer, A., Nieswandt, B., Andrews, R. K., Parker, M. W., Gardiner, E. E. and Peter, K. (2015) Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators. The Journal of Experimental Medicine, 212 (2). pp. 129-137. ISSN 1540-9538 doi: 10.1084/jem.20140391

Abstract/Summary

Nucleotide-based drug candidates such as antisense oligonucleotides, aptamers, immunoreceptor-activating nucleotides, or (anti)microRNAs hold great therapeutic promise for many human diseases. Phosphorothioate (PS) backbone modification of nucleotide-based drugs is common practice to protect these promising drug candidates from rapid degradation by plasma and intracellular nucleases. Effects of the changes in physicochemical properties associated with PS modification on platelets have not been elucidated so far. Here we report the unexpected binding of PS-modified oligonucleotides to platelets eliciting strong platelet activation, signaling, reactive oxygen species generation, adhesion, spreading, aggregation, and thrombus formation in vitro and in vivo. Mechanistically, the platelet-specific receptor glycoprotein VI (GPVI) mediates these platelet-activating effects. Notably, platelets from GPVI function-deficient patients do not exhibit binding of PS-modified oligonucleotides, and platelet activation is fully abolished. Our data demonstrate a novel, unexpected, PS backbone-dependent, platelet-activating effect of nucleotide-based drug candidates mediated by GPVI. This unforeseen effect should be considered in the ongoing development programs for the broad range of upcoming and promising DNA/RNA therapeutics.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/44789
Identification Number/DOI 10.1084/jem.20140391
Refereed Yes
Divisions Life Sciences > School of Biological Sciences > Biomedical Sciences
Publisher Rockefeller University Press
Download/View statistics View download statistics for this item

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar